The majority of autologous CAR-T cell therapies involve ... Fate Therapeutics is at the forefront of programmed cellular immunotherapy developments designed to treat cancer and immune disorders.

CAR-Ts are revolutionising the treatment of blood cancers such as B-cell acute lymphocytic leukaemia. However, their success has not yet extended to the realm of solid tumours, as no CAR-T therapy has ...

Now a new approach using donor cells brings the hope of giving off-the-shelf CAR T cell immunotherapy to patients in as little as five days. Conventional autologous CAR T therapy requires cells to be ...

CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next ...

The TILVANCE-301 trial will compare immunotherapy plus adoptive cell ... most promising TCRT at present is the investigational autologous cell therapy IMA203 (NCT03688124), which targets the ...

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) has achieved a major milestone in the fight against acute myeloid leukemia ...

The funding includes contributions from new investors such as Baylor College of Medicine and the Brain Tumor Investment Fund.

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant ... such as intensive chemotherapy, immunotherapy, targeted drugs ...

“This second FDA Fast Track designation of our autologous dendritic cell vaccines for pancreatic cancer is another acknowledgement of the incredible potential of this innovative immunotherapy ...